Extended betrixaban in the medically ill: a comparison of fatal or irreversible events with standard treatment

Join Dr Alexander Cohen for a discussion of his study: Comparison of fatal or irreversible events with extended‐duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy

This live journal club will be hosted on GoToWebinar, and requires users to complete a quick registration form in order to access the session. This will allow you to pose questions directly to our chair and speaker during the session, and provide an email when the journal club is about to begin.

Extended betrixaban in the medically ill: a comparison of fatal and irreversible events with standard treatment

29/11/201718:30 GMT30 minutes

Add to your calendar

Speaker

Dr Cohen

Dr Alexander Cohen

Guy's and St Thomas’ Hospitals

London, UK

Topic

Patients who are hospitalised for acute medical illnesses are at an increased risk for venous thromboembolism. Betrixaban recently became the first NOAC to receive approval for extended-duration thromboprophylaxis after hospital discharge in this patient population. In this journal club, we take a look at the most recent post-hoc analysis to emerge from the APEX trial, which considers the impact of betrixaban on fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin.

View abstract  access full paper

  • Target audience

    This educational activity is designed for hospitalists, haematologists, interventional cardiologists, internists, surgeons, and any other healthcare professional with an interest or role in thromboprophylaxis or the management of the acutely medically ill.

  • Disclosures

    ACHL staff, PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Accreditation

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and PCM Scientific. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

    Credit designation

    The Academy for Continued Healthcare Learning designated this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Funding

    This independent educational activity is supported by funding from Portola Pharmaceuticals. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run independently of the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.